Cargando…

Author Correction: Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis

Detalles Bibliográficos
Autores principales:	Aljayyoussi, Ghaith, Tyrer, Hayley E., Ford, Louise, Sjoberg, Hanna, Pionnier, Nicolas, Waterhouse, David, Davies, Jill, Gamble, Joanne, Metuge, Haelly, Cook, Darren A. N., Steven, Andrew, Sharma, Raman, Guimaraes, Ana F., Clare, Rachel H., Cassidy, Andrew, Johnston, Kelly L., Myhill, Laura, Hayward, Laura, Wanji, Samuel, Turner, Joseph D., Taylor, Mark J., Ward, Stephen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5773522/ https://www.ncbi.nlm.nih.gov/pubmed/29348597 http://dx.doi.org/10.1038/s41598-018-19723-1

Ejemplares similares

Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis
por: Aljayyoussi, Ghaith, et al.
Publicado: (2017)

A murine macrofilaricide pre-clinical screening model for onchocerciasis and lymphatic filariasis
por: Halliday, Alice, et al.
Publicado: (2014)

Boron-Pleuromutilins as Anti-Wolbachia Agents with Potential for Treatment of Onchocerciasis and Lymphatic Filariasis
por: Jacobs, Robert T., et al.
Publicado: (2019)

Corrigendum: Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
por: Sharma, Raman, et al.
Publicado: (2018)

Minocycline as a re-purposed anti-Wolbachia macrofilaricide: superiority compared with doxycycline regimens in a murine infection model of human lymphatic filariasis
por: Sharma, Raman, et al.
Publicado: (2016)

Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives
por: Wan Sulaiman, Wan Aliaa, et al.
Publicado: (2019)

Anti-Wolbachia drug discovery and development: safe macrofilaricides for onchocerciasis and lymphatic filariasis
por: TAYLOR, MARK J., et al.
Publicado: (2014)

Repurposing of approved drugs from the human pharmacopoeia to target Wolbachia endosymbionts of onchocerciasis and lymphatic filariasis
por: Johnston, Kelly L., et al.
Publicado: (2014)

Albendazole and antibiotics synergize to deliver short-course anti-Wolbachia curative treatments in preclinical models of filariasis
por: Turner, Joseph D., et al.
Publicado: (2017)

Evaluation of Lymphatic Filariasis and Onchocerciasis in Three Senegalese Districts Treated for Onchocerciasis with Ivermectin
por: Wilson, Nana O., et al.
Publicado: (2016)

The impact of ivermectin on onchocerciasis in villages co-endemic for lymphatic filariasis in an area of onchocerciasis recrudescence in Burkina Faso
por: Nikièma, Achille S., et al.
Publicado: (2021)

Repurposing Auranofin as a Lead Candidate for Treatment of Lymphatic Filariasis and Onchocerciasis
por: Bulman, Christina A., et al.
Publicado: (2015)

Wolbachia endosymbionts induce neutrophil extracellular trap formation in human onchocerciasis
por: Tamarozzi, Francesca, et al.
Publicado: (2016)

Serological Evaluation of Onchocerciasis and Lymphatic Filariasis Elimination in the Bakoye and Falémé Foci, Mali
por: Dolo, Housseini, et al.
Publicado: (2020)

Wolbachia depletion blocks transmission of lymphatic filariasis by preventing chitinase-dependent parasite exsheathment
por: Quek, Shannon, et al.
Publicado: (2022)

Eliminating Lymphatic Filariasis, Onchocerciasis, and Schistosomiasis from the Americas: Breaking a Historical Legacy of Slavery
por: Lammie, Patrick J., et al.
Publicado: (2007)

Validation of ultrasound bioimaging to predict worm burden and treatment efficacy in preclinical filariasis drug screening models
por: Marriott, Amy E., et al.
Publicado: (2018)

Using Community-Level Prevalence of Loa loa Infection to Predict the Proportion of Highly-Infected Individuals: Statistical Modelling to Support Lymphatic Filariasis and Onchocerciasis Elimination Programs
por: Schlüter, Daniela K, et al.
Publicado: (2016)

Developing Eradication Investment Cases for Onchocerciasis, Lymphatic Filariasis, and Human African Trypanosomiasis: Rationale and Main Challenges
por: Tediosi, Fabrizio, et al.
Publicado: (2013)

Short-course, oral flubendazole does not mediate significant efficacy against Onchocerca adult male worms or Brugia microfilariae in murine infection models
por: Sjoberg, Hanna T., et al.
Publicado: (2019)

Development of Pyrazolopyrimidine Anti-Wolbachia Agents for the Treatment of Filariasis
por: McGillan, Paul, et al.
Publicado: (2021)

Impact of Three Rounds of Mass Drug Administration on Lymphatic Filariasis in Areas Previously Treated for Onchocerciasis in Sierra Leone
por: Koroma, Joseph B., et al.
Publicado: (2013)

Loa loa vectors Chrysops spp.: perspectives on research, distribution, bionomics, and implications for elimination of lymphatic filariasis and onchocerciasis
por: Kelly-Hope, Louise, et al.
Publicado: (2017)

Potential Value of Triple Drug Therapy with Ivermectin, Diethylcarbamazine, and Albendazole (IDA) to Accelerate Elimination of Lymphatic Filariasis and Onchocerciasis in Africa
por: Fischer, Peter U., et al.
Publicado: (2017)

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Côte d’Ivoire
por: Loukouri, Agodio, et al.
Publicado: (2020)

Integrated transmission assessment surveys (iTAS) of lymphatic filariasis and onchocerciasis in Cross River, Taraba and Yobe States, Nigeria
por: Anagbogu, Ifeoma N., et al.
Publicado: (2022)

Intracellular PD Modelling (PD(i)) for the Prediction of Clinical Activity of Increased Rifampicin Dosing
por: Aljayyoussi, Ghaith, et al.
Publicado: (2019)

AWZ1066S, a highly specific anti-Wolbachia drug candidate for a short-course treatment of filariasis
por: Hong, W. David, et al.
Publicado: (2019)

Impact of repeated annual community directed treatment with ivermectin on loiasis parasitological indicators in Cameroon: Implications for onchocerciasis and lymphatic filariasis elimination in areas co-endemic with Loa loa in Africa
por: Wanji, Samuel, et al.
Publicado: (2018)

Tetracyclines improve experimental lymphatic filariasis pathology by disrupting interleukin-4 receptor–mediated lymphangiogenesis
por: Furlong-Silva, Julio, et al.
Publicado: (2021)

Status of Onchocerciasis Transmission after More Than a Decade of Mass Drug Administration for Onchocerciasis and Lymphatic Filariasis Elimination in Central Nigeria: Challenges in Coordinating the Stop MDA Decision
por: Evans, Darin S., et al.
Publicado: (2014)

MDA—Lymphatic Filariasis
por: Ichimori, Kazuyo
Publicado: (2014)

Urban lymphatic filariasis
por: Simonsen, Paul E., et al.
Publicado: (2012)

Assessment of the burden of soil-transmitted helminthiasis after five years of mass drug administration for Onchocerciasis and Lymphatic filariasis in Kebbi State, Nigeria
por: Oluwole, Akinola Stephen, et al.
Publicado: (2017)

Mouse models of Loa loa
por: Pionnier, Nicolas P., et al.
Publicado: (2019)

Endpoints for Lymphatic Filariasis Programs
por: Grady, Caroline A., et al.
Publicado: (2007)

Mapping of lymphatic filariasis in Nepal
por: Sherchand, Jeevan B, et al.
Publicado: (2003)

Elimination of Lymphatic Filariasis in The Gambia
por: Rebollo, Maria P., et al.
Publicado: (2015)

The history of the elimination of lymphatic filariasis in China
por: De-jian, Sun, et al.
Publicado: (2013)

Lymphatic Filariasis Disseminating to the Upper Extremity
por: Maldjian, Catherine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_c8m7tchna2budacvmisf4p373h